Aptose Biosciences Inc.
Records under this name other than the patents Aptose Biosciences Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Aptose Biosciences Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,279,703 | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof Lapsed on the fee record Ended Mar 22, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 22, 2026 | From the USPTO record |
| US 11,149,047 | Aryl imidazoles for treatment of cancer Lapsed on the fee record Ended Oct 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 19, 2025 | From the USPTO record |
| US 11,104,957 | Compositions and methods for treating cancers Lapsed on the fee record Ended Aug 31, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 31, 2025 | From the USPTO record |
| US 10,080,739 | Aryl Imidazoles and Their Use as Anti-Cancer Agents Term ended Term ended Aug 9, 2025 · High confidence | Term ended | Term ended Aug 9, 2025 | High confidence |
| US 9,567,643 | Compositions and methods for treating cancers Lapsed on the fee record Ended Feb 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 14, 2025 | From the USPTO record |
| US 8,148,392 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer Lapsed on the fee record Ended Apr 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2024 | From the USPTO record |
| US 8,394,815 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Term ended Ended no later than Aug 19, 2023 · From the USPTO record | Term ended | Ended no later than Aug 19, 2023 | From the USPTO record |
| US 8,987,305 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Lapsed on the fee record Ended Mar 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2023 | From the USPTO record |
| US 8,969,372 | Aryl imidazoles and their use as anti-cancer agents Lapsed on the fee record Ended Mar 3, 2023 · Medium confidence | Lapsed on the fee record | Ended Mar 3, 2023 | Medium confidence |
| US 7,884,120 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Lapsed on the fee record Ended Feb 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 8, 2023 | From the USPTO record |